Litcius/Paper detail

ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA

Michael J. Koren, Alexis Hofherr, Jennifer Schumi, Dinko Rekić, Jane Knöchel, Catarina Nilsson, Anna Rudvik, Linda Wernevik, Tina Rydén‐Bergsten, Björn Carlsson

2022Journal of the American College of Cardiology18 citationsDOI

Topics & Concepts

MedicineTolerabilityDyslipidemiaPCSK9OligonucleotidePharmacologyInternal medicineAdverse effectCholesterolLDL receptorDiseaseGeneGeneticsLipoproteinBiologySystemic Lupus Erythematosus ResearchHepatitis C virus researchBiochemical and Molecular Research
ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA | Litcius